Was I proven right, after speculating about MPOX PCR tests for Africa last night?
WHO press release suggests I was
Here is what I wrote last night:
“The WHO never once said what its teams are going to actually do. Or if any doctors or nurses were part of teams. They are not sending in imprecise PCR kits to gin up the cases and deaths, are they?”
And this morning, it looks like that might be exactly the plan:
Wednesday, 30 October 2024
News Release
WHO lists additional mpox diagnostic tests for emergency use
As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure. WHO’s EUL is based on the review of quality, safety and performance data in compliance with international standards while addressing the specific needs of low- and middle-income countries (LMICs).
Polymerase Chain Reaction (PCR) testing, which detects viral DNA, is considered the gold standard for diagnosing mpox infection.
WHO listed the Xpert Mpox, a real-time PCR test manufactured by Cepheid under its EUL procedure, on 25 October. This test is designed for use on compatible GeneXpert systems. The Xpert Mpox test is easy to operate and delivers results in under 40 minutes. Once the cartridge is placed in the system, the process is fully automated, with real-time PCR detecting viral DNA of monkeypox virus clade II. The GeneXpert system is a near-point-of-care testing option, which can support decentralized testing.
Another PCR-based option, the cobas MPXV assay, developed by Roche Molecular Systems, Inc., was listed on 14 October 2024. It is intended for use on the cobas 6800/8800 Systems. This tool is a real-time PCR test capable of detecting both mpox clades and delivering results in under 2 hours. It can process multiple samples simultaneously and is suitable for clinical laboratories that handle large volumes of tests.
“Ensuring global access to mpox diagnostic tests that meet WHO standards for quality, safety and performance is essential for efficient and effective testing in settings affected by mpox outbreaks,” said Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification. “Rapid access to those listed products is critical not only for prompt diagnosis and timely treatment but also for effectively containing the spread of the virus."
WHO previously listed Alinity m MPXV assay, manufactured by Abbott Molecular Inc. under EUL on 3 October.
In 2024, 18 countries have reported over 40 000 suspected mpox cases with most remaining unconfirmed due to limited testing capacity, especially in LMICs. In the Democratic Republic of the Congo—the hardest-hit country—testing has significantly increased in 2024, following efforts to decentralize testing with support from WHO and partners. However, the proportion of tested cases remains low, accounting for 40-50% of the suspected cases.
Would be “fun” to know what cycle threshold they are using for the MPox PCR testing.
When still wondering why the Democratic Republic of the Congo remains in focus, it's this:
---
Located in central Africa, the Democratic Republic of Congo or Congo Kinshasa is considered to be the world’s wealthiest country regarding its natural resources. In fact, its unexploited deposits of minerals are estimated to be approximately worth 24 trillion United States Dollars (USD). Despite all this vast potential, the DRC unfortunately still remains a poor nation. What a paradox.
https://afrikta.com/biggest-natural-resources-in-congo-drc/
---
IOW living in a region rich in nonrenewable resources has become a manmade risk factor for health (and death, via war or "natural disaster".